Emerging analyses on retatrutide, a dual agonist for incretin hormone and gastric inhibitory polypeptide, suggest significant findings in addressing weight gain and type 2 diabetes. Initial information from clinical trials reveal considerable decreases in body mass and enhanced glucose regulation. more info Further exploration is focused on long-te